The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials

Marijke Coomans*, Linda Dirven, Neil K. Aaronson, Brigitta G. Baumert, Martin van den Bent, Andrew Bottomley, Alba A. Brandes, Olivier Chinot, Corneel Coens, Thierry Gorlia, Ulrich Herrlinger, Florence Keime-Guibert, Annika Malmstrom, Francesca Martinelli, Roger Stupp, Andrea Talacchi, Michael Weller, Wolfgang Wick, Jaap C. Reijneveld, Martin J. B. TaphoornEORTC Quality Life Grp, EORTC Brain Tumor Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Web of Science)

Abstract

Objective: Prognostic value of health-related quality of life (HRQoL) data may be important to inform patients in clinical practice and to guide clinical decision-making. Our study investigated the added prognostic value of HRQoL for overall survival (OS) and progression-free survival (PFS) in a large heterogeneous sample of glioma patients, besides known prognostic factors.

Methods: We included individual baseline data from previously published randomised controlled trials (RCTs) in glioma patients in which HRQoL was assessed through the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BN20 questionnaires. Multivariable Cox regression models (stratified for newly diagnosed versus recurrent disease) were constructed, first with clinical variables (age, sex, tumour type, performance status, allocated treatment and extent of resection) only and subsequently with HRQoL variables added, separately for OS and PFS. The added prognostic value of HRQoL was calculated using C-indices.

Results: Baseline HRQoL and clinical data from 15 RCTs were included, comprising 5217 patients. In the model including both clinical and HRQoL variables, better cognitive and role functioning and less motor dysfunction were independently associated with longer OS, whereas better role and cognitive functioning, less nausea and vomiting and more appetite loss were independently associated with prolonged PFS. However, C-indices indicated only a small prognostic improvement of the models for OS and PFS when adding HRQoL to the clinical prognostic variables (+1.1% for OS and +.7% for PFS).

Conclusion: Our findings demonstrate that several baseline HRQoL variables are independently prognostic for OS and PFS, yet the added value of HRQoL to the known clinical prognostic variables was small. (C) 2019 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)190-198
Number of pages9
JournalEuropean Journal of Cancer
Volume116
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Glioma
  • Health-related quality of life (HRQoL)
  • Prognostic factor
  • Brain tumour
  • Survival
  • PHASE-III
  • PREDICTING SURVIVAL
  • CANCER-PATIENTS
  • COGNITIVE FUNCTION
  • CLINICAL-TRIALS
  • BRAIN-TUMOR
  • EORTC
  • GLIOBLASTOMA
  • VALIDATION
  • SYMPTOMS

Cite this